Moffitt Notice of Blackbaud Data Incident. Learn More
Clinical Trials Search
Phase II Open-Label, Randomized Study of PARP inhibition (Olaparib) Either Alone or in Combination with Anti-PD-L1 Therapy (Atezolizumab; MPDL3280A) in Homologous DNA Repair (HDR) Deficient, Locally Advanced or Metastatic Non-HER2-positive Breast Cancer
This randomized phase II trial studies how well veliparib and atezolizumab work either alone or in combination in treating patients with stage III-IV triple negative breast cancer. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as atezolizumab, may interfere with the ability of tumor cells to grow and spread. It is not known whether giving veliparib and atezolizumab either alone or in combination would work better in patients with triple negative breast cancer.
Primary Objectives: To compare the progression free survival (PFS) among three study arms, i.e., ABT-888 monotherapy (arm 1), atezolizumab monotherapy (arm 2), and ABT-888 + atezolizumab in combination (arm 3) based on normal RECIST criteria in patients with advanced triple negative breast cancer (TNBC) harboring homologous DNA repair (HDR) through BRCA 1/2 mutation.
Atezolizumab (Tecentriq); Olaparib (Lynparza)